{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:00:51Z","timestamp":1791097251112,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":5336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.nurt.2008.10.042","type":"journal-article","created":{"date-parts":[[2008,12,25]],"date-time":"2008-12-25T05:41:37Z","timestamp":1230183697000},"page":"152-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Memoquin: A Multi-Target\u2013Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease"],"prefix":"10.1016","volume":"6","author":[{"given":"Maria Laura","family":"Bolognesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Melchiorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nurt.2008.10.042_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer's disease","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimer Dementia"},{"key":"10.1016\/j.nurt.2008.10.042_bib2","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","article-title":"Global prevalence of dementia: a Delphi consensus study","volume":"366","author":"Ferri","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.nurt.2008.10.042_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1517\/14728214.10.4.817","article-title":"Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors?","volume":"10","author":"Small","year":"2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.nurt.2008.10.042_bib4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1126\/science.1132813","article-title":"100 years and counting: prospects for defeating Alzheimer's disease","volume":"314","author":"Roberson","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.nurt.2008.10.042_bib5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.nurt.2008.10.042_bib6","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1471-4159.2006.04211.x","article-title":"Disease modifying therapy for AD?","volume":"99","author":"Golde","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.nurt.2008.10.042_bib7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/35086072","article-title":"Alzheimer's disease and Abeta toxicity: from top to bottom","volume":"2","author":"Small","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.nurt.2008.10.042_bib8","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/437942a","article-title":"Drug discovery: playing dirty","volume":"437","author":"Frantz","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.nurt.2008.10.042_bib9","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0197-4580(00)00191-3","article-title":"Alzheimer disease is multifactorial and heterogeneous","volume":"21","author":"Iqbal","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.nurt.2008.10.042_bib10","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands","volume":"48","author":"Morphy","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1586\/14737175.4.5.799","article-title":"Utilizing combination therapy in the treatment of Alzheimer's disease","volume":"4","author":"Farlow","year":"2004","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.nurt.2008.10.042_bib12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000122962","article-title":"Treatment options in Alzheimer's disease: maximizing benefit, managing expectations","volume":"25","author":"Farlow","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.nurt.2008.10.042_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1513\/pats.200504-037SR","article-title":"Pharmacologic principles for combination therapy","volume":"2","author":"Toews","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.nurt.2008.10.042_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib15","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1185\/030079907X233403","article-title":"A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch","volume":"23","author":"Small","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.nurt.2008.10.042_bib16","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/156720507783018226","article-title":"Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties","volume":"4","author":"Van der Schyf","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.nurt.2008.10.042_bib17","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1021\/jm9810452","article-title":"Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease","volume":"41","author":"Melchiorre","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0024-3205(93)90307-O","article-title":"Therapeutic potential of CNS-active M2 antagonists: novel structures and pharmacology","volume":"52","author":"Doods","year":"1993","journal-title":"Life Sci"},{"key":"10.1016\/j.nurt.2008.10.042_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/092986706775527974","article-title":"Dimeric and hybrid anti-Alzheimer drug candidates","volume":"13","author":"Munoz-Torrero","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib20","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1523\/JNEUROSCI.18-09-03213.1998","article-title":"Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils","volume":"18","author":"Alvarez","year":"1998","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.10.042_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/A:1022416505725","article-title":"Brain acetylcholinesterase promotes amyloid-beta-peptide aggregation but does not hydrolyze amyloid precursor protein peptides","volume":"23","author":"Campos","year":"1998","journal-title":"Neurochem Res"},{"key":"10.1016\/j.nurt.2008.10.042_bib22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0896-6273(00)80108-7","article-title":"Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme","volume":"16","author":"Inestrosa","year":"1996","journal-title":"Neuron"},{"key":"10.1016\/j.nurt.2008.10.042_bib23","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1074\/jbc.274.5.2963","article-title":"Crystal structure of mouse acetylcholinesterase","volume":"274","author":"Bourne","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1389557013406864","article-title":"Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease","volume":"1","author":"Castro","year":"2001","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib25","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.2174\/1381612043383313","article-title":"Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics","volume":"10","author":"Recanatini","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nurt.2008.10.042_bib26","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.2174\/138161206778792985","article-title":"Targeting Beta-amyloid pathogenesis through acetylcholinesterase inhibitors","volume":"12","author":"Castro","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nurt.2008.10.042_bib27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/med.10029","article-title":"Polymethylene tetraamine backbone as template for the development of biologically active polyamines","volume":"23","author":"Melchiorre","year":"2003","journal-title":"Med Res Rev"},{"key":"10.1016\/j.nurt.2008.10.042_bib28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2174\/138955708785740652","article-title":"From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease","volume":"8","author":"Bolognesi","year":"2008","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-3-7091-7508-8_30","article-title":"Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study","volume":"54","author":"Gutzmann","year":"1998","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.nurt.2008.10.042_bib30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/PL00005296","article-title":"Idebenone protects hippocampal neurons against amyloid beta-peptide-induced neurotoxicity in rat primary cultures","volume":"358","author":"Hirai","year":"1998","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.nurt.2008.10.042_bib31","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1089\/ars.2007.1703","article-title":"Alzheimer's disease: a lesson from mitochondrial dysfunction","volume":"9","author":"Moreira","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.nurt.2008.10.042_bib32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00023210-199809050-00006","article-title":"Idebenone: a review of its use in mild to moderate Alzheimer's disease","volume":"9","author":"Adkins","year":"1998","journal-title":"CNS Drugs"},{"key":"10.1016\/j.nurt.2008.10.042_bib33","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1002\/anie.200700256","article-title":"A small molecule targeting the multifactorial nature of Alzheimer's disease","volume":"46","author":"Cavalli","year":"2007","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.nurt.2008.10.042_bib34","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1002\/anie.200500845","article-title":"In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers","volume":"44","author":"Nesterov","year":"2005","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.nurt.2008.10.042_bib35","unstructured":"Bolognesi ML, Banzi R, Minarini A, Melchiorre C, inventors. Process for preparation of 1,4-benzoquinone-2,5-diamines by reaction of amines with 1,4-benzoquinones bearing leaving groups at the 2- and 5-positions. PCT Int Appl WO 2006134457."},{"key":"10.1016\/j.nurt.2008.10.042_bib36","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1021\/jm070559a","article-title":"Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease","volume":"50","author":"Bolognesi","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib37","unstructured":"Andrisano V, Bartolini M, Bolognesi ML, Cavalli A, Melchiorre C, Recanatini M, inventors. Preparation of 2,5-bis-diamine-[1,4]benzoquinone derivatives for the treatment of Alzheimer's disease and a process for their preparation and intermediates therefor. PCT Int Appl WO 2003087035."},{"key":"10.1016\/j.nurt.2008.10.042_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/tx970136j","article-title":"Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone)","volume":"11","author":"Mordente","year":"1998","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.nurt.2008.10.042_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1179\/135100099101534701","article-title":"Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer's disease","volume":"4","author":"Raina","year":"1999","journal-title":"Redox Rep"},{"key":"10.1016\/j.nurt.2008.10.042_bib40","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00702-004-0242-8","article-title":"Oxidative stress mechanisms and potential therapeutics in Alzheimer disease","volume":"112","author":"Moreira","year":"2005","journal-title":"J Neural Transm"},{"key":"10.1016\/j.nurt.2008.10.042_bib41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0197-4580(03)00117-9","article-title":"Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease","volume":"25","author":"SantaCruz","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.nurt.2008.10.042_bib42","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0076-6879(04)82021-4","article-title":"Induction of quinone reductase as a primary screen for natural product anticarcinogens","volume":"382","author":"Kang","year":"2004","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.nurt.2008.10.042_bib43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbrc.2007.07.125","article-title":"How to understand the dichotomy of antioxidants","volume":"362","author":"Shen","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nurt.2008.10.042_bib44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0006-2952(02)01514-9","article-title":"Beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies","volume":"65","author":"Bartolini","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.nurt.2008.10.042_bib45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1006\/jmbi.1997.1245","article-title":"Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils","volume":"272","author":"Alvarez","year":"1997","journal-title":"J Mol Biol"},{"key":"10.1016\/j.nurt.2008.10.042_bib46","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1021\/jm049156q","article-title":"Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation","volume":"48","author":"Bolognesi","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib47","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1021\/jm0340602","article-title":"3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy","volume":"46","author":"Piazzi","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib48","doi-asserted-by":"crossref","first-page":"14845","DOI":"10.1021\/bi051613x","article-title":"Discovery of acetylcholinesterase peripheral anionic site ligands through computational refinement of a directed library","volume":"44","author":"Dickerson","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.nurt.2008.10.042_bib49","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1021\/jm0503289","article-title":"Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease","volume":"48","author":"Munoz-Ruiz","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib50","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1021\/jm070154q","article-title":"Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation","volume":"51","author":"Xie","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib51","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1021\/jm8001313","article-title":"Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation","volume":"51","author":"Camps","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1358\/dot.2003.39.1.740206","article-title":"The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease","volume":"39","author":"Rees","year":"2003","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.nurt.2008.10.042_bib53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbrc.2005.02.132","article-title":"Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro","volume":"330","author":"Ono","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nurt.2008.10.042_bib54","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1074\/jbc.271.12.6839","article-title":"Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin","volume":"271","author":"Tomiyama","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib55","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/cbic.200700427","article-title":"Insight into the kinetic of amyloid beta (1\u201342) peptide self-aggregation: elucidation of inhibitors' mechanism of action","volume":"8","author":"Bartolini","year":"2007","journal-title":"Chembiochem"},{"key":"10.1016\/j.nurt.2008.10.042_bib56","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0014-5793(00)02380-2","article-title":"Anti-amyloidogenic activity of tetracyclines: studies in vitro","volume":"487","author":"Forloni","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.nurt.2008.10.042_bib57","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1474-4422(02)00188-6","article-title":"Secretases as targets for the treatment of Alzheimer's disease: the prospects","volume":"1","author":"Dewachter","year":"2002","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nurt.2008.10.042_bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrd2314","article-title":"Therapies for Alzheimer's disease","volume":"6","author":"Melnikova","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nurt.2008.10.042_bib59","doi-asserted-by":"crossref","first-page":"6826","DOI":"10.1073\/pnas.97.12.6826","article-title":"Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice","volume":"97","author":"Capsoni","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.10.042_bib60","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10571-006-9112-2","article-title":"On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease","volume":"26","author":"Capsoni","year":"2006","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.nurt.2008.10.042_bib61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/mcne.2002.1163","article-title":"Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies","volume":"21","author":"Capsoni","year":"2002","journal-title":"Mol Cell Neurosci"},{"issue":"3 Suppl 1","key":"10.1016\/j.nurt.2008.10.042_bib62","first-page":"S73","article-title":"S4-04-04 Memoquin, a novel multifunctional compound for Alzheimer's disease: An up-date on preclinical studies","volume":"2","author":"Capsoni","year":"2006","journal-title":"Alzheimer Dementia"},{"key":"10.1016\/j.nurt.2008.10.042_bib63","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1021\/jm000285q","article-title":"Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor","volume":"43","author":"Liu","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.042_bib64","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0197-4580(00)00114-7","article-title":"NAD(P)H:quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Alzheimer's disease","volume":"21","author":"Wang","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.nurt.2008.10.042_bib65","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbrc.2007.07.124","article-title":"Oxidative stress: A dead end or a laboratory hypothesis?","volume":"362","author":"Azzi","year":"2007","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923004464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923004464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurt.2008.10.042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:39:27Z","timestamp":1761806367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923004464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1878747923004464"],"URL":"https:\/\/doi.org\/10.1016\/j.nurt.2008.10.042","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Memoquin: A Multi-Target\u2013Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nurt.2008.10.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}